<DOC>
	<DOCNO>NCT00023309</DOCNO>
	<brief_summary>This study evaluate safety effectiveness lamivudine plus adefovir versus adefovir alone treat chronic hepatitis B infection . The Food Drug Administration approve lamivudine treatment hepatitis B . However , drug effective patient , many initially work develop resistance 1 3 year . Adefovir experimental drug inhibits replication hepatitis B virus ( HBV ) . Adefovir use alone may adequate provide sustain suppression virus improvement liver disease . However combine two anti-viral agent may superior use one alone , similar strategy employ treatment AIDS . This study test whether combination lamivudine adefovir good adefovir alone treatment chronic hepatitis B . Patients 18 year age old , infected HBV least 6 month , may eligible study . Candidates may receive lamivudine treatment past 6 month prior treatment adefovir must take anti-viral treatment hepatitis . They blood test confirm HBV infection . Participants admit NIH Clinical Center 2 3 day medical evaluation . One 2 week evaluation , patient randomize begin take lamivudine adefovir , adefovir alone . Therapy continue least 12 month . Follow-up clinic visit schedule weekly first month , every 4 8 week rest treatment period . Patients evaluate end 1 year . Patients improved treatment stop take treatment evaluate clinic every 4 week another 6 month . Patients show improvement liver injury may continue take lamivudine adefovir adefovir alone 4 year , long continue improve medication . Progress evaluate . If test result show continued improvement negative hepatitis B antigens , therapy stop . Patients continue treatment 5 year readmitted year 4 another medical evaluation ass effect treatment time . After 5 year patient stop therapy follow regular clinic visit least 6 month .</brief_summary>
	<brief_title>Lamivudine Adefovir Treat Chronic Hepatitis B</brief_title>
	<detailed_description>Aims : To assess safety , antiviral activity clinical benefit combination lamivudine adefovir dipivoxil v adefovir alone 80 patient chronic hepatitis B five year . Background : Adefovir dipivoxil lamivudine oral antiviral agent show potent activity HBV vitro vivo . Both drug use extensively patient HIV infection recently control trial monotherapy patient chronic hepatitis B. Lamivudine currently approve therapy hepatitis B evaluate extensively one-year course treatment well long-term continuous therapy . While lamivudine monotherapy induces transient improvement viral level liver histology , viral resistance develop large proportion patient re-appearance HBV DNA serum high level associate mutation Tyrosine-methionine-aspartate-aspartate ( YMDD ) motif HBV polymerase gene worsen hepatitis . Adefovir monotherapy , contrast , show associate development viral resistance even give two year . When give monotherapy 1 year , adefovir lead improvement histology hepatitis B approximately 50 % patient . At present , long-term efficacy adefovir show . Protocol : Up 80 patient chronic hepatitis B raise serum ALT ( alanine aminotransferase ) level , HBV DNA serum ( 1 million copy per ml quantitative PCR ) active liver disease liver biopsy enrol started combination lamivudine ( 100 mg daily ) adefovir dipivoxil ( 10 mg daily ) adefovir alone ( 10 mg daily ) . Patients stratify one four group 20 patient randomization : ( A ) Lamivudine naive HBeAg positive , ( B ) Lamivudine naive HBeAg negative ( C ) previous lamivudine therapy HBeAg positive ( D ) previous lamivudine therapy HBeAg negative . Patients monitor carefully therapy adverse event , clinical symptom sign liver disease , biochemical , hematological parameter , HBV serology 2 4 week interval . The primary endpoint therapy maintain combined response ( combination virological , biochemical , histological response ) major time end-points 1 4 year . Secondary endpoint include loss HBeAg , individual type maintain response ( virological , biochemical histological ) , development lamivudine resistance , improvement symptom score quality life assessment 1 4 year . Conclusions : This study assess effect combination lamivudine adefovir dipivoxil compare adefovir alone suppress hepatitis B prevention lamivudine resistant mutant arise long-term therapy lamivudine alone .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great 18 year , male female Known serum HBsAg positivity least 6 month Detectable HBVDNA serum 1 million copy per ml , detect quantitative PCR ( Roche Cobas Assay ) Serum ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) level upper limit normal base two determination take least one month apart 6 month entry Liver biopsy within 2 year consistent chronic hepatitis histology activity index score ( HAI ) 6 ( total possible score 22 ) `` Ishak '' fibrosis score least 1 ( total possible score 6 ) . For patient lamivudine resistance liver biopsy may perform either lamivudine . Written informed consent . EXCLUSION CRITERIA : Previous current treatment adefovir tenofovir . Coinfection HDV ( Hepatitis D Virus ) define presence antiHDV serum HDV antigen liver Coinfection HCV ( Hepatitis C Virus ) define presence antiHCV HCV RNA serum . Coinfection HIV ( Human immunodeficiency virus ) define presence antiHIV serum . Decompensated liver disease define serum bilirubin great 2.5 mg % , prothrombin time great 2 second prolonged , serum albumin le 3.0 gm % , history ascites , variceal bleeding , hepatic encephalopathy . Presence cause liver disease ( i.e. , hemochromatosis , Wilson 's disease , alcoholic liver disease , nonalcoholic steatohepatitis , alpha1 antitrypsin deficiency ) A history organ transplantation absence organ transplantation , immunosuppressive therapy require use 5 mg prednisone ( equivalent ) daily . Significant systemic illness liver disease include congestive heart failure , renal failure , chronic pancreatitis , diabetes mellitus poor control opinion investigator might interfere therapy . Pregnancy inability practice contraception patient capable bear father child Preexisting bone marrow suppression : White Blood Cells ( WBC ) less 2,000 cells/mm ( 3 ) , hematocrit less 30 % , platelets less 50,000 cells/mm ( 3 ) . History clinically apparent pancreatitis evidence subclinical pancreatitis show serum amylase value twice upper limit normal range abnormality pancreas CT image study abdomen Prior interferon treatment within 6 month entry Sensory motor neuropathy apparent medical history physical examination Creatinine clearance le 50 ml/min serum creatinine great 1.5 mg/dl ; creatinine clearance determine 24 hour urine specimen . Accuracy collection ensure document appropriate total creatinine excretion 24 hour urine specimen ( 15 mg/kg ) correct patient 's age gender . Concurrent use nephrotoxic agent ( e.g. , aminoglycosides , amphotericin B , vancomycin , foscarnet , cisplatinum , pentamidine , nonsteroidal antiinflammatory agent ) competitor renal tubular excretion ( e.g. , probenecid ) within 2 month prior study screen expectation subject receive course study History hypersensitivity nucleoside/nucleotide analogues Active ethanol/drug abuse/psychiatric problem , investigator 's opinion , might interfere participation study History seizure disorder History renal tubular acidosis History malignancy treatment malignancy within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Adefovir Dipivoxil</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Nucleoside/Nucleotide Analogue</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Hepatitis B Mutants</keyword>
	<keyword>Liver Biopsy</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>HBV</keyword>
	<keyword>Liver</keyword>
</DOC>